Phase 3 Trial of Agalsidase Beta in Pediatric Patients with Fabry Disease

Andrew Black
Published Online: Monday, Feb 20, 2017
A Phase 3b clinical trial assessing agalsidase beta in lowering pediatric Fabry patient’s globotriaosylceramide [GL-3] levels in skin, plasma and urine showed encouraging results for treatment.
The trial was a Phase 3b randomized, open-label, parallel-group study assessing agalsidase beta in ERT-naive male Fabry patients aged 5-18 years old. Skin biopsies were obtained at ERT-baseline at years 1, 3 and 5, or at early withdrawal.
 Patients were administered at low dose regimens, i.e. 0.5 mg/kg every 2 weeks (0.5q2w, n=16) or 1.0 mg/kg every 4 weeks (1.0q4w, n=15) for 5 years.


13 out of 20 (65%) patients with a non-zero superficial skin capillary endothelium (SSCE) GL-3 score at baseline reached and maintained zero scores (7 on 0.5q2w, 6 on 1.0q4w).
Shifts from baseline non-zero to zero SSCE GL-3 scores were statistically significant at each time point in the overall study population and both treatment groups, except at year 5 in the 1.0q4w group.
No patient had severe SSCE GL-3 accumulation (score of 3) at any time point. All patients with IgG peak titer ≤6400 showed complete and sustained GL-3 clearance in SSCE.
Patients with the highest peak IgG titers tended to show less robust GL-3 clearance in SSCE.


About agalsidase beta

Agalsidase beta is a recombinant human α-galactosidase A enzyme with the same amino acid sequence as the native enzyme.


Ramaswami U, et al. A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium. Presented at 13th Annual WORLDSymposium; February 13-17, 2017; San Diego, CA.

About Fabry disease

Fabry disease is an X-linked lysosomal storage disorder that leads to excessive deposition of globotriaosylceramide (GL-3) throughout the body. Skin, eye, kidney, heart, brain, and peripheral nervous system are highly vulnerable.
The condition is caused by deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) which degrades GL-3. The accumulation of GL-3 is believed to cause a variety of symptoms, including pain, kidney failure, and increased risk of heart attack and stroke.

Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$